Electrocortical Activity in Older Adults Is More Influenced by Cognitive Task Complexity Than Concurrent Walking

Human cognitive-motor performance largely depends on how brain resources are allocated during simultaneous tasks. Nonetheless, little is known regarding the age-related changes in electrocortical activity when dual-task during walking presents higher complexity levels. Thus, the aim of this study was to investigate whether there are distinct changes in walking performance and electrocortical activation between young and older adults performing simple and complex upper limb response time tasks. Physically active young (23 ± 3 years, n = 21) and older adults (69 ± 5 years, n = 19) were asked to respond as fast as possible to a single stimuli or a double stimuli appearing on a touch screen during standing and walking. Response time, step frequency, step frequency variability and electroencephalographic (EEG) N200 and P300 amplitudes and latencies from frontal central and parietal brain regions were recorded. The results demonstrated that older adults were 23% slower to respond to double stimuli, whereas younger adults were only 12% slower (p 0.05). More importantly, the P300 amplitude was significantly reduced for older adults when responding to double stimuli regardless of standing or walking tasks (p < 0.05), with no changes in younger participants. Therefore, physically active older adults can attenuate potential walking deficits experienced during dual-task walking in simple cognitive tasks. However, cognitive tasks involving decision making influence electrocortical activation due to reduced cognitive resources to cope with the task demands

Astrophysical Weighted Particle Magnetohydrodynamics

This paper presents applications of weighted meshless scheme for conservation laws to the Euler equations and the equations of ideal magnetohydrodynamics. The divergence constraint of the latter is maintained to the truncation error by a new meshless divergence cleaning procedure. The physics of the interaction between the particles is described by an one-dimensional Riemann problem in a moving frame. As a result, necessary diffusion which is required to treat dissipative processes is added automatically. As a result, our scheme has no free parameters that controls the physics of inter-particle interaction, with the exception of the number of the interacting neighbours which control the resolution and accuracy. The resulting equations have the form similar to SPH equations, and therefore existing SPH codes can be used to implement the weighed particle scheme. The scheme is validated in several hydrodynamic and MHD test cases. In particular, we demonstrate for the first time the ability of a meshless MHD scheme to model magneto-rotational instability in accretion disks.Comment: 27 pages, 24 figures, 1 column, submitted to MNRAS, hi-res version can be obtained at http://www.strw.leidenuniv.nl/~egaburov/wpmhd.pd

The 21cm "Outer Arm" and the Outer-Galaxy High-Velocity Clouds: Connected by Kinematics, Metallicity, and Distance

Using high-resolution ultraviolet spectra obtained with the HST/Space Telescope Imaging Spectrograph (STIS) and the Far Ultraviolet Spectroscopic Explorer, we study the metallicity, kinematics, and distance of the gaseous "Outer Arm" (OA) and the high-velocity clouds (HVCs) in the outer Galaxy. We detect the OA in a variety of absorption lines toward two QSOs, H1821+643 and HS0624+6907. We search for OA absorption toward eight Galactic stars and detect it in one case, which constrains the OA Galactocentric radius to 9<R_{G}<18 kpc. We also detect HVC Complex G, which is projected near the OA at a similar velocity, in absorption toward two stars; Complex G is therefore in the same region at R_{G} = 8 - 10 kpc. HVC Complex C is known to be at a similar Galactocentric radius. Toward H1821+643, the low-ionization absorption lines are composed of multiple narrow components, indicating the presence of several cold clouds and rapid cooling and fragmentation. Some of the highly ionized gas is also surprisingly cool. Accounting for ionization corrections, we find that the OA metallicity is Z=0.2-0.5 Z_{solar}, but nitrogen is underabundant and some species are possibly mildly depleted by dust. The similarity of the OA metallicity, Galactocentric location, and kinematics to those of the adjacent outer-Galaxy HVCs, including high velocities that are not consistent with Galactic rotation, suggests that the OA and outer-Galaxy HVCs could have a common origin.Comment: Accepted for publication in the Astrophysical Journa

Translocation of the Na+/H+ exchanger 1 (NHE1) in cardiomyocyte responses to insulin and energy-status signalling

The Na+/H+ exchanger NHE1 is a highly regulated membrane protein that is required for pH homoeostasis in cardiomyocytes. The activation of NHE1 leads to proton extrusion, which is essential for counteracting cellular acidity that occurs following increased metabolic activity or ischaemia. The activation of NHE1 intrinsic catalytic activity has been well characterized and established experimentally. However, we have examined in the present study whether a net translocation of NHE1 to the sarcolemma of cardiomyocytes may also be involved in the activation process. We have determined the distribution of NHE1 by means of immunofluorescence microscopy and cell-surface biotinylation. We have discovered changes in the distribution of NHE1 that occur when cardiomyocytes are stimulated with insulin that are PI3K (phosphoinositide 3-kinase)-dependent. Translocation of NHE1 also occurs when cardiomyocytes are challenged by hypoxia, or inhibition of mitochondrial oxidative metabolism or electrically induced contraction, but these responses occur through a PI3K-independent process. As the proposed additional level of control of NHE1 through translocation was unexpected, we have compared this process with the well-established translocation of the glucose transporter GLUT4. In immunofluorescence microscopy comparisons, the translocation of NHE1 and GLUT4 to the sarcolemma that occur in response to insulin appear to be very similar. However, in basal unstimulated cells the two proteins are mainly located, with the exception of some co-localization in the perinuclear region, in distinct subcellular compartments. We propose that the mechanisms of translocation of NHE1 and GLUT4 are linked such that they provide spatially and temporally co-ordinated responses to cardiac challenges that necessitate re-adjustments in glucose transport, glucose metabolism and cell pH

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)